This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lilenbaum RC , Huber RM , Treat J , Masters G , Kaubitzsch S , Lane S , Wissel P
Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status
Clinical Lung Cancer. 2006 Sep;8(2) :130-134
AbstractPURPOSE: Topotecan is generally well tolerated and active in patients with relapsed small-cell lung cancer (SCLC) and poor performance status (PS). In this study, we investigated whether treatment with topotecan is associated with improvement in PS as measured by the rate of conversion from PS 2 to PS 0/1. PATIENTS AND METHODS: A retrospective analysis of data from 7 clinical trials (N = 795) investigating topotecan in patients with relapsed SCLC was performed. All patients received topotecan 1.25-1.5 mg/m(2) daily on days 1-5 of a 21-day cycle. Demographics were similar for patients with PS 2 and PS 0/1. A total of 152 patients with PS 2 at baseline received 502 cycles (median, 2 cycles; range, 1-14 cycles) of therapy, and 32 (21%) experienced PS improvement to PS 0/1 that lasted for >= 2 cycles. RESULTS: Overall, 50% of patients who experienced PS conversion also exhibited an objective antitumor response, compared with 8% of patients with PS 2 who had no improvement in PS and achieved a response. Similarly, median overall survival was longer for patients with PS improvement (37 weeks; 95% confidence interval, 29.6-49.4 weeks) compared with patients with PS 2 who had a response but no PS improvement (10.4 weeks; 95% confidence interval, 8.7-13.6 weeks). A substantial proportion of patients with PS 2 and relapsed SCLC experienced PS improvement during topotecan treatment. These patients had a substantially longer median survival and a higher response rate compared with the overall trial population. CONCLUSION: Improvement in PS appears to be a good indicator of benefit from topotecan therapy.
NotesISI Document Delivery No.: 107LR Times Cited: 0 Cited Reference Count: 33 Cited References: AGRA Y, 2003, COCHRANE DATABASE SY ARDIZZONI A, 1997, J CLIN ONCOL, V15, P2090 CERSOSIMO RJ, 2002, AM J HEALTH-SYST PH, V59, P611 CHARLSON ME, 1987, J CHRON DIS, V40, P373 CHEN TT, 2000, J NATL CANCER I, V92, P1601 CHUTE JP, 1999, J CLIN ONCOL, V17, P1794 DEPIERRE A, 1997, LUNG CANCER S1, V18, P35 ECKARDT J, 1996, ANN ONCOL, V7, P107 EINHORN LH, 1986, SEMIN ONCOL, V13, P5 GRALLA RJ, 2004, ONCOLOGIST S6, V9, P14 GRUNBERG SM, 1999, CANCER CHEMOTH PHARM, V44, P461 HUBER RM, 2006, EUR RESPIR J, V27, P1183 JOHNSON BE, 2002, CLIN CHEST MED, V23, P225 KAWAHARA M, 1997, JPN J CLIN ONCOL, V27, P158 KOSMIDIS PA, 1994, SEMIN ONCOL, V21, P23 KUSUMOTO S, 1986, JPN J CLIN ONCOL, V16, P319 LILENBAUM R, 2004, CLIN LUNG CANC, V5, P209 LUDBROOK JJS, 2003, INT J RADIAT ONCOL, V55, P1321 MILLER AB, 1981, CANCER, V47, P207 NEUBAUER M, 2004, J CLIN ONCOL, V22, P1872 OSOBA D, 1994, ONCOLOGY, V8, P61 OSTERLIND K, 1986, CANCER RES, V46, P4189 PAGE NC, 2002, P AN M AM SOC CLIN, V21, A305 SAIJO N, 2003, BRIT J CANCER, V89, P2178 SAKURAGI T, 1996, JPN J CLIN ONCOL, V26, P128 SCHILLER JH, 2001, ONCOLOGY-BASEL S1, V61, P3 SCHILLER JH, 2002, NEW ENGL J MED, V346, P92 SPIEGELMAN D, 1989, J CLIN ONCOL, V7, P344 SUNDSTROM S, 2002, J CLIN ONCOL, V20, P4665 TAN EH, 1995, ANN ACAD MED SINGAP, V24, P812 TREAT J, 2004, ONCOLOGIST, V9, P173 VONPAWEL J, 1999, J CLIN ONCOL, V17, P658 VONPAWEL J, 2001, J CLIN ONCOL, V19, P1743